Amgen’s 1st-qtr better-than-expected; ups full-year guidance
US biotech major Amgen (Nasdaq: AMGN) posted first-quarter 2015 financial results after markets closed on Tuesday, posting earnings and sales that beat consensus analysts’ forecasts. The firm’s shares gained 2.13% to $175.05 in after-hours trading.
Amgen’s net income came in at $1.62 billion, up 51%, or $2.11 per share, up from $1.07 billion, or $1.40 per share, in the 2014 first quarter. After excluding costs for layoffs and other restructuring and integrating the acquisition of Onyx, adjusted net income was $1.91 billion, or $2.48 per share (+33%). Analysts surveyed by FactSet were expecting $2.10. Revenue for the quarter totaled $5.03 billion, a rise of 11% year-on-year, beating forecasts of $4.92 billion.
2015 guidance
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze